Clinical trial examines whether Ambroxol can slow dementia in people with Parkinson's Dementia poses a major health challenge with no safe, affordable treatments to slow its progression.
https://www.news-medical.net/n....ews/20250701/Clinica

Current FDA Safety Investigation: NAION With Mounjaro, Zepbound, and Other GLP-1 RAs Evaluating Glucagon-like Peptide-1 (GLP-1) Receptor Agonists for Possible Risk of NAION Side Effects (Posted by Tom Lamb at Drug Injury Watch) The FDA has been investigating "potential signals" of non-arteritic anterior ischemic optic neuropathy (NAION) with the glucagon-like peptide-1 (GLP-1) receptor agonist class of drugs. For example, NAION with Mounjaro, Zepbound, Wegovy, Rybelsus, and Ozempic. From "October - December 2024 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)", here is a full list of the glucagon-like peptide-1 (GLP-1) receptor agonists, or GLP-1 RAs, that are being evaluated: Adlyxin (lixisenatide) injection Bydureon (exenatide) for extended-release injectable suspension Bydureon BCise (exenatide extended-release) injectable suspension Byetta (exenatide) injection Mounjaro (tirzepatide) injection Ozempic (semaglutide) injection Rybelsus (semaglutide) tablets Saxenda (liraglutide) injection Soliqua 100/33 (insulin glargine and lixisenatide) injection Trulicity (dulaglutide) injection Victoza (liraglutide) injection Wegovy (semaglutide) injection Xultophy 100/3.6 (insulin degludec and liraglutide) injection Zepbound (tirzepatide) injection In early June 2025, the European Medicines Agency (EMA) confirmed the link between the semaglutide-containing drugs Wegovy, Rybelsus, and Ozempic and NAION (non-arteritic anterior ischemic optic neuropathy). This drug regulator went on to say a NAION warning would be added to the drug labels for Wegovy, Rybelsus, and...
https://www.drug-injury.com/dr....uginjurycom/2025/06/

HonorHealth study shows major breakthrough in treating structural shock An 8-year HonorHealth Research Institute clinical trial, using non-surgical techniques, showed 86% of patients with a type of usually fatal low blood pressure known as 'structural shock' survived at least 3 months, while 73% survived at least 6 months, according to a study presented here at a major heart convention.
https://www.news-medical.net/n....ews/20250627/HonorHe

Insilico Medicine begins clinical trial for AI-designed cancer drug ISM3412 Insilico Medicine, a clinical-stage biotechnology company driven by generative artificial intelligence (AI), today announces that the first patient has been dosed in a global multicenter clinical trial (NCT0641446 to evaluate ISM3412, a potentially best-in-class, AI-empowered MAT2A inhibitor with novel structure, in patients with locally advanced and metastatic solid tumors.
https://www.news-medical.net/n....ews/20250627/Insilic

Tirzepatide rewires appetite and slashes calorie intake in new obesity trial A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with overweight or obesity, outperforming liraglutide and placebo. Brain imaging revealed that tirzepatide also lowered neural responses to high-fat, high-sugar food cues, offering mechanistic insight into its potent weight-loss effects.
https://www.news-medical.net/n....ews/20250625/Tirzepa